Ambrx, a clinical stage biopharmaceutical company, and China-based pharmaceutical Zhejiang Medicine (ZMC) are collaborating to develop and commercialize ARX788, Ambrx’s internally developed, site-specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer.
Ambrx and ZMC will develop ARX788, with ZMC bearing the ongoing development cost. ZMC will receive commercial rights in China while Ambrx retains commercial rights outside of China and receives royalties on all sales. ZMC will manufacture the product for clinical and commercial supplies on a global basis. WuXi PharmaTech will provide integrated services for ARX788, including developing and manufacturing the toxin, antibody and ADC, preclinical development and clinical trials.
"The partnership will help ZMC undertake pioneering work in the development of monoclonal antibodies and ADCs,” said Chunbo Li, chairman of ZMC.
"Our collaboration with Ambrx and ZMC on ARX788 is another example of how WuXi's comprehensive, integrated, open-access R&D services platform enables our partners to develop innovative products efficiently and cost-effectively to benefit the world's patients," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech.